Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer

In a retrospective cohort study of patients with oligo-progressive metastatic breast cancer, researchers investigated the use of metastasis-directed stereotactic radiotherapy to all sites of cancer progression while patients remained on their same systemic therapy. The researchers concluded that this patient population, particularly patients with HR+ HER2- disease, benefited from this multimodal treatment strategy.